



Circulation

 FREE ACCESS | ABSTRACT

GRFW AND UNDERREPRESENTED POPULATIONS

SESSION TITLE: PREVENTION AND TREATMENT OF CAD IN WOMEN

Abstract 9773: Nourin Mirnas: Novel Blood Biomarkers for Early Identification or Exclusion of Myocardial Ischemia in Women Suspected of Having Coronary Artery Disease (CAD)

Salwa A Elgebaly, Robert H Christenson, Michael Azrin, Hussien Rizk, Nashwa El-Khazragy, Don Kreutzer, Charles Van Buren and Robert Poston

Originally published 30 Oct 2022 | Circulation. 2022;146:A9773

Abstract

Introduction: Women are frequently present with *questionable angina*. Lack of specificity and sensitivity in imaging procedures and absence of a blood-based biomarker that can detect myocardial ischemia *earlier than cell death*, may contribute to women being under-investigated and under-treated, with worse outcomes. *The blood-based biomarkers, Nourin protein and its regulatory miRNAs (miR-137 and miR-106b) are elevated in the setting of myocardial ischemia before it progresses to infarction.*

Hypothesis: Unlike hs-TnI, Nourin-dependent miR-137 and miR-106b can identify or exclude myocardial ischemia in patients suspected of having CAD, as proven by stress test results.

Methods: Serum levels of Nourin miRNAs (qPCR) and plasma hs-TnI were measured *blindly* in: 1) chest pain patients suspected of having CAD (n=12) both before stress ECHO/ECG test (pre-test) and 30 minutes after test completion (post-test); 2) STEMI patients (n=16); and 3) healthy subjects (n=16).

Results: 1) very low baseline levels of Nourin miRNAs in healthy (range: 1.38 to 1.43) and CAD negative (range: 1.84 to 4.53); 2) significant upregulation of *miR-137* (2,156 pre and 2,574 post) and *miR-106b* (423 pre and 521 post) in CAD positive (n=5) compared to CAD negative (n=7) (range: 1.84 to 4.53) pre-test (continuous release in response to chronic myocardial ischemia) and post-test; 3) higher levels in STEMI (4,509 (miR-137) and 950 (miR-106b) pre) compared to CAD (2,156 and 423 pre); 4) over 86% sensitivity and 100% specificity that can "rule out" myocardial ischemia, just as

NT-proBNP for heart failure and D-dimer for deep vein thrombosis; and 5) hs-TnI was elevated only in STEMI, but not in CAD patients, pre & post.

Conclusions: *Assessment of Nourin miRNAs enables the identification of a population of patients with ischemia, but without injury or infarction, and exclusion of myocardial ischemia, based on its strong negative predictive value, thus potentially improving the treatment algorithms for women.*




Figure 1: Serum levels of miR-137 and miR-106b measured at baseline “pre-stress test” (a and c) and 30 minutes after ECHO/ECG stress test “post-stress test” (b and d) in positive (+ve) CAD patients (n=7), negative (-ve) CAD patients (n=7), and STEMI patients (n=16) compared to healthy subjects (n=16). Data are expressed as mean and SE. Abbreviations: CAD: Coronary artery disease, STEMI: ST-elevation myocardial infarction, and SE: Standard error of mean.

[Download figure](#)

Footnotes

Author Disclosures: For author disclosure information, please visit the AHA Scientific Sessions 2022 [Online Program Planner](#) and search for the abstract title.



[^ Back to top](#)



Circulation

AHA Journals

Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)

Circulation

Circ: Arrhythmia and Electrophysiology

Circ: Genomic and Precision Medicine

Circ: Cardiovascular Imaging

Circ: Cardiovascular Interventions

Circ: Cardiovascular Quality & Outcomes

Circ: Heart Failure

Circulation Research

Hypertension

Journal of the American Heart Association (JAHA)

Stroke

Stroke: Vascular and Interventional Neurology

AIM: Clinical Cases

Journal Information

About

Editorial Board

Reprints

Customer Service and Ordering Information

AHA Journals RSS Feeds

For International Users

Institutions/Librarians FAQ

For Subscribers

Subscriber Help

Wolters Kluwer Privacy Policy

Subjects

All Subjects

Arrhythmia and Electrophysiology

Basic, Translational, and Clinical Research

Critical Care and Resuscitation

Epidemiology, Lifestyle, and Prevention

Genetics

Heart Failure and Cardiac Disease

Hypertension

Imaging and Diagnostic Testing

Intervention, Surgery, Transplantation

Quality and Outcomes

Stroke

Vascular Disease

Features



Bridging Disciplines

Circulation at Major Meetings

Special Themed Issues

Global Impact of the 2017 ACC/AHA Hypertension Guidelines

Circulation Supplements

Cardiovascular Case Series

ECG Challenge

Hospitals of History

On My Mind

Podcast Archive

- Circulation on the Run

- Subscribe to Circulation on the Run

- #FITFAVES

Circulation Doodle

Resources & Education



AHA Guidelines and Statements

Circulation CME

Information for Advertisers

For Authors & Reviewers



Instructions for Authors

Submission Site

AHA Journals EDI Editorial Board

Author Reprints



American Heart Association®

National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service
1-800-AHA-USA-1
1-800-242-8721

[Local Info](#)
[Contact Us](#)

ABOUT US

- [About the AHA/ASA](#) >
- [2016-17 Annual Report](#) >
- [AHA Financial Information](#) >
- [Careers](#) >
- [SHOP](#) >
- [Latest Heart and Stroke News](#) >
- [AHA/ASA Media Newsroom](#) >
- [Global Programs](#) >

OUR SITES

- [American Heart Association](#) >
- [American Stroke Association](#) >
- [Professional Heart Daily](#) >

[More Sites](#) >

TAKE ACTION

[Advocate](#) >

[Donate](#) >

[Planned Giving](#) >

[Volunteer](#) >

ONLINE COMMUNITIES

[AFib Support](#) >

[Garden Community](#) >

[Patient Support Network](#) >

[Privacy Policy](#) | [Copyright](#) | [Ethics Policy](#) | [Conflict of Interest Policy](#) | [Linking Policy](#) | [Diversity](#) | [Careers](#) |

[Suppliers & Providers](#) | [Accessibility Statement](#) | [State Fundraising Notices](#)

© American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is qualified 501(c)(3) tax-exempt organization.

*Red Dress TM DHHS, Go Red TM; AHA; National Wear Red Day [®] is registered trademark.

